Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes by Grivas, Petros et al.
This is the author manuscript accepted for publication and has undergone full peer review but 
has not been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this article 
as doi: 10.xxxx/cncr.31817 
This article is protected by copyright. All rights reserved 
 
DR. SUMANTA KUMAR PAL (Orcid ID : 0000-0002-1712-0848) 
DR. PETER HUGH O'DONNELL (Orcid ID : 0000-0003-2650-0049) 
 
 
Article type      : Original Article 
 
 
Original article 
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial 
carcinoma and inactivating alterations of acetyltransferase genes  
Petros Grivas
1,2
, Amir Mortazavi
3
, Joel Picus
4
, Noah M. Hahn
5
, Matthew Milowsky
6
, Lowell 
Hart
7
, Ajjai Alva
8
, Joaquim Bellmunt
9
, Sumanta Pal
10
, Richard Bambury
11
, Peter H. 
O’Donnell
12
, Sumati Gupta
13
, Elizabeth Guancial
14
, Guru Sonpavde
9
, Demiana Faltaos
15
,  
Diane Potvin
15
, James Christensen
15
, Richard Chao
15
, Jonathan E. Rosenberg
1. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland 
Clinic, Cleveland, OH (during this trial)  
2. Department of Medicine, Division of Oncology, University of Washington School of 
Medicine and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, 
WA (present) 
3. Department of Medicine, Division of Medical Oncology, The Ohio State University 
Comprehensive Cancer Center, Columbus, OH 
4. Washington University in St. Louis, St Louis, MO 
5. Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer 
Center, Baltimore, MD 
6. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 
16
 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
7. Florida Cancer Specialists, Fort Myers, FL 
8. University of Michigan, Ann Arbor, MI 
9. Dana Farber Cancer Institute, Boston, MA 
10. City of Hope, Duarte, CA 
11. Cork University Hospital, Cork, Ireland 
12. University of Chicago, Chicago, IL 
13. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 
14. Wilmot Cancer Institute, University of Rochester, Rochester, NY (during the conduct of 
this study; now affiliated with Florida Cancer Specialists, Fort Myers, FL) 
15. Mirati Therapeutics Inc., San Diego, CA 
16. Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medical 
College, New York, NY 
 
Corresponding author: Dr. Jonathan E. Rosenberg 
Memorial Sloan Kettering Cancer Center 
1275 York Avenue 
New York 
NY, 10065 
Email: rosenbj1@mskcc.org
 
 
Telephone: 001-646-422-4461 
Text pages: 25 
Tables: 2 
Figures: 2 
 
Funding 
This work was supported by Mirati Therapeutics, Inc. 
 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
Disclosures  
Amir Mortazavi has served as a consultant / advisory board member for Genentech/Roche 
and received honoraria from Motive Medical Intelligence; his institution has received 
research funding from Mirati Therapeutics for the conduct of this trial and from Acerta 
Pharma, Merck, Genentech/Roche, Novartis, Seattle Genetics and Bristol-Myers Squibb for 
the conduct of other studies. 
Noah Hahn has served as a consultant for OncoGeneX, AstraZeneca, Merck, Bristol-Myers 
Squibb, Genentech, Inovio, Principia Biopharma, Ferring, TARIS, Eli Lilly, Advanced Health, 
TARIS Biomedical, Seattle Genetics, Rexahn and Pieris Pharmaceuticals, and received 
honoraria from Bladder Cancer Academy; his institution has received research funding from 
Mirati Therapeutics for the conduct of this trial and from OncoGeneX, Seattle Genetics, 
Merck, Genentech, Bristol-Myers Squibb, AstraZeneca, Principia Biopharma, Pieris 
Pharmaceuticals and Inovio for the conduct of other studies. 
Matthew Milowsky has served as a consultant for BioClin Therapeutics; his institution 
received research funding from Mirati Therapeutics for the conduct of this trial and from 
Acerta Pharma, Astellas, Seattle Genetics, Bristol-Myers Squibb, Incyte, Merck, Pfizer and 
Roche/Genentech for the conduct of other studies. 
Joaquim Bellmunt has served as a consultant for Pfizer, AstraZeneca, Merck, Roche, Bristol-
Myers Squibb and Pierre Fabre; his institution received research funding from Mirati 
Therapeutics for the conduct of this trial. 
Richard Bambury has nothing to disclose. 
Peter O’Donnell has received honoraria from Algeta ASA, American Medical Forum, Astellas, 
AstraZeneca/MedImmune, Genentech/Roche, Harrison Consulting, Inovio Pharmaceuticals, 
Janssen Biotech, Kantar Health, Merck, Novartis, Parexel, Quintiles, Seattle Genetics and 
Xceda. He has provided expert testimony to Trinity Health and Temple Health, owns stock in 
Allergan and is a co-inventor of a genomic prescribing system (patent pending). His 
institution received research funding from Mirati Therapeutics for the conduct of this trial, 
and from Genetech/Roche, Merck, Boehringer Ingelheim, Acerta Pharma, Seattle Genetics, 
Janssen Biotech, and AstraZeneca/MedImmune for the conduct of other trials.  
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
The institute of Sumati Gupta received research funding from Mirati Therapeutics for the 
conduct of this trial and received research support from Bristol-Myers Squibb, Five Prime 
Therapeutics, Hoosier Oncology Group, Incyte, LSK BioPharma, Merck, Novartis, Pfizer and 
Rexahn Pharmaceuticals for the conduct of other clinical trials.  
Sumanta Pal has served as a consultant for Astellas, GlaxoSmithKlein, Bristol-Myers Squibb, 
Exelixis, Novartis, Pfizer and Genentech, and received honoraria from Genentech; his 
institution received research funding from Mirati Therapeutics for the conduct of this trial. 
Guru Sonpavde has served as a consultant for Bristol-Myers Squibb, Exelixis, Bayer, Sanofi, 
Pfizer, Novartis, Eisai, Janssen, Amgen, AstraZeneca, Merck, Genentech, Pfizer, 
Biotheranostics, National Comprehensive Cancer Network and Astellas/Agensys, acted as a 
speaker for Clinical Care Options, Physicians Education Resource, Research to Practice and 
Onclive, and received author royalties from UpToDate; his institution has received 
research/clinical trial support from Celgene, Bayer, Onyx-Amgen, Boehringer-Ingelheim, 
Merck, and Pfizer. 
Elizabeth Guancial has served as a consultant to Taris and a member of the speaker bureau 
for Genetech; her institution received research funding from Mirati Therapeutics for the 
conduct of this trial. 
The institutions of Ajjai Alva, Joel Picus and Lowell Hart received research funding from 
Mirati Therapeutics for the conduct of this trial. 
Jonathan Rosenberg has served as a consultant to Genentech/Roche, Bristol-Myers Squibb, 
Merck, AstraZeneca, Inovio, Bayer, Seattle Genetics, Mirati Therapeutics, BioClin, EMD 
Serono, QED Therapeutics and Astellas; his institution received research funding from Mirati 
Therapeutics for the conduct of this trial, and research funding from AstraZeneca, 
Genentech/Roche, Astellas and Seattle Genetics for the conduct of other trials.  
Petros Grivas has served as consultant for Genentech/Roche, Bristol-Myers Squibb, Merck & 
Co, AstraZeneca, EMD Serono, Clovis Oncology, Foundation Medicine, Driver Inc., Seattle 
Genetics, Dendreon, Bayer, Pfizer, Exelis, QED Therapeutics and Biocept; his institution 
received research funding from Mirati Therapeutics for the conduct of this trial and research 
funding from Genentech/Roche, Bayer, Merck & Co, Mirati Therapeutics, Oncogenex, Pfizer, 
Bristol-Myers Squibb, AstraZeneca, Clovis Oncology for the conduct of other trials. 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
James Christensen, Demiana Faltos and Richard Chao are employees of Mirati 
Therapeutics.  
Diane Potvin is a paid consultant of Mirati Therapeutics. 
 
 
Author contributions: 
Jonathan Rosenberg: conceptualization, methodology, resources, investigation, writing – 
original draft, writing – reviewing and editing 
Petros Grivas: methodology, resources, investigation, writing – original draft, writing – 
reviewing and editing 
Ajjai Alva, Richard Bambury, Joaquim Bellmunt, Elizabeth Guancial, Sumati Gupta, Noah 
Hahn, Lowell Hart, Amir Mortazavi, Matthew Milowsky, Peter O’Donnell, Sumanta Pal, 
Joel Picus, Guru Sonpavde: resources, investigation, writing – reviewing and editing 
Demiana Faltaos and Diane Potvin: data curation, formal analysis, writing – reviewing and 
editing 
Richard Chao: methodology, formal analysis, writing – reviewing and editing, visualization, 
and project administration 
James Christensen: conceptualization, methodology, formal analysis, writing – reviewing 
and editing, visualization, and project administration 
 
Abstract 
Background: We evaluated mocetinostat (Class I/IV histone de-acetylase [HDAC] inhibitor) 
in urothelial carcinoma harboring inactivating mutations or deletions in CREBBP and/or 
EP300 (histone acetyltransferase genes) in a single-arm, open-label Phase II study. 
Methods: Eligible patients with platinum-treated, advanced/metastatic disease received 
oral mocetinostat (70 mg three times per week [TIW] escalating to 90 mg TIW) in 28-day 
cycles in a 3-stage study (NCT02236195). The primary endpoint was objective response rate 
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(ORR). 
Results: Genomic testing was feasible in 155/175 patients (89%). Qualifying tumor 
mutations were: CREBBP (15%), EP300 (8%), and both CREBBP and EP300 (1%). Seventeen 
patients were enrolled into Stage 1 (ITT population); no patients were enrolled in 
subsequent stages. One partial response was observed (11% [1/9; efficacy evaluable 
population which comprised 9/15 planned patients]); activity was deemed insufficient to 
progress to Stage 2 (null hypothesis: ORR ≤15%). All patients experienced ≥1 adverse event, 
most commonly nausea (77% [13/17]) and fatigue (71% [12/17]). Median treatment 
duration was 46 days; treatment interruptions (82% [14/17]) and dose reductions (29% 
[5/17]) were common. Mocetinostat exposure was lower than anticipated (dose-normalized 
Cmax
 
 following TIW dosing 0.2 ng/mL/mg). 
Conclusions: To our knowledge, this study represents the first clinical trial using genomic-
based selection to identify patients with urothelial cancer likely to benefit from selective 
HDAC inhibition. Mocetinostat was associated with significant toxicities that impacted drug 
exposure and may have contributed to modest clinical activity in these pretreated patients. 
The efficacy observed was considered insufficient to warrant further investigation of 
mocetinostat as a single agent in this setting. 
Key words: mocetinostat, urothelial carcinoma, CREBBP, EP300, histone deacetylase 
Running head: Mocetinostat in advanced urothelial cancer 
 
Condensed abstract:  
Following genomic-based selection of urothelial cancer patients with inactivating 
mutations/deletions in the histone acetyltransferase genes CREBBP and/or EP300, single-
agent mocetinostat was associated with significant toxicities that limited drug exposure. 
This may have contributed to limited activity (response rate 11%) in the heavily pretreated 
platinum-refractory patients in this Phase II study. 
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Introduction 
Urothelial carcinoma of the upper urinary tract and bladder results in 165,000 deaths 
annually worldwide 
1
. Most patients with metastatic disease progress despite platinum-
based chemotherapy, and salvage chemotherapy has only modest efficacy 
2, 3
. Recently, five 
immune checkpoint inhibitors were approved for platinum-refractory urothelial carcinoma, 
and while the anti-programmed death protein-1 (PD1) agent, pembrolizumab has improved 
overall survival (OS) versus chemotherapy in this setting, many patients do not benefit from 
such therapy 
4
Dysregulated histone acetylation is implicated in the pathogenesis of several cancers, 
including urothelial carcinoma. Acetylation of chromatin by histone acetyltransferases 
(HATs) is generally associated with elevated transcription, while deacetylation, mediated by 
histone de-acetylases (HDACs), is associated with repressed transcription 
. Consequently, new treatment options are needed. 
5, 6
. Histone 
acetylation can become dysregulated through the upregulation of HDACs, and/or genetic 
inactivation of HATs, resulting in silencing of tumor supressor and other genes 
5, 6
. Inhibition 
of HDAC1 and HDAC2 resulted in antitumor activity in urothelial carcinoma in vitro, while in 
urothelial carcinoma patients elevated HDAC1 is linked with poor prognosis 
7, 8
. HDAC 
inhibitors have shown promise in clinical trials across a range of tumor types and several are 
approved by the FDA including vorinostat for cutaneous T-cell lymphoma (CTCL), romidepsin 
for CTCL and peripheral T-cell lymphoma (PTCL), belinostat for PTCL, and panobinostat for 
multiple myeloma 
9
Mocetinostat is an investigational HDAC inhibitor that targets Class I and IV HDACs (isoforms 
1, 2, 3, and 11) 
.  
10
, and has demonstrated anti-tumor activity in patients with hematologic 
malignancies 
11-13
. In vivo, mocetinostat induces cell cycle arrest, apoptosis and inhibits 
tumor growth 
10
. Furthermore, a HAT inactivation signature associated with muscle-invasive 
bladder cancer was inversely influenced by mocetinostat in breast cancer cells 
14
. 
Mocetinostat also demonstrated preferential activity in CREBBP- and EP300-mutated (HAT 
genes) xenograft models and solid tumor cell lines, including urothelial cell carcinoma 
(Supplementary Tables S1, S2; Supplementary Figure S1). Thus, we hypothesized that 
treating urothelial carcinoma harboring inactivating mutations in CREBBP and EP300 with 
selective HDAC inhibitors may restore expression of tumor suppressor genes, resulting in 
anti-tumor responses. 
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This Phase II study investigated single-agent mocetinostat in patients with locally advanced 
or metastatic urothelial carcinoma previously treated with platinum-based chemotherapy 
and inactivating tumor mutations or deletions in CREBBP and/or EP300.  
 
Methods 
Patients and study design 
This Phase II, open-label, single-arm, 3-stage, multicenter study was conducted between 
November 2014 and July 2016 (ClinicalTrials.gov, NCT02236195). Patients with histologically 
confirmed, locally advanced, unresectable or metastatic urothelial (transitional cell) 
carcinoma who progressed following platinum-based chemotherapy were recruited. Eligible 
patients had adequate bone marrow, hepatic and renal function and an inactivating 
mutation or deletion (homozygous or hemizygous) in CREBBP and/or EP300 (see 
supplementary appendix). Genomic prescreening of tumor tissue (primary or metastatic, 
archival tissue was permitted if a fresh biopsy was not available) was performed centrally 
using next-generation sequencing (NGS; Foundation Medicine; Cambridge, MA, USA) or a 
Sponsor-approved, local sequencing platform (FoundationOne®, MSK-IMPACT™) or NGS 
(Oncopanel, Center for Advanced Molecular Diagnostics, Brigham and Women’s Hospital, 
Boston, MA, USA) capturing the full coding regions for CREBBP and EP300. Key exclusion 
criteria included prior or current treatment with an HDAC inhibitor and symptomatic or 
uncontrolled brain metastases.  
Oral mocetinostat (Mirati Therapeutics, Inc. San Diego, US) was administered in continuous 
28-day cycles at a starting dose of 70 mg three times per week (TIW) for Stage 1. Escalation 
to 90 mg TIW on Cycle 2 Day 1 was planned for patients without treatment-related Grade ≥3 
adverse events (AEs), and 90 mg TIW was the planned starting dose for the Stage 2 and 3 
cohorts. Mocetinostat was continued until disease progression or unacceptable AEs.  
The protocol was approved by the Institutional Review Boards at each institution, and the 
study was conducted in accordance with the Declaration of Helsinki and the International 
Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided 
written, informed consent. 
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Study endpoints and assessments 
The primary endpoint was objective response rate (ORR: complete response [CR] and partial 
response [PR] per RECIST v1.1 ). Secondary endpoints included duration of response (DoR), 
progression-free survival (PFS: overall and at month 4), OS, 1-year survival rate, safety and 
pharmacokinetics.  
CT scans for tumor evaluation were performed at baseline, 8-week intervals for the first 12 
months, and 12-week intervals thereafter. AEs were graded per NCI CTCAE Version 4.03.  
Plasma concentrations of mocetinostat were determined using high performance liquid 
chromatography and tandem mass spectrometry during Stage 1 (pre-dose and 1 h post-dose 
on day 1 of cycles 1 and 2) with more timepoints planned for Stage 2.  
Tumor total mutation burden (TMB) was estimated retrospectively in the 322 target genes 
included in FoundationOne for patients with central testing (see supplementary appendix).  
 
Statistical analyses 
The primary endpoint (ORR) was assessed using an exact test for single proportion (two-
sided α=5%; ORR ≤15% [H0] vs >15% [ H1
 
]) in a three-stage study design to include 15, 18, 
and 67 patients, respectively, in the efficacy evaluable population (patients meeting the 
entry criteria who received mocetinostat and had at least baseline and one on-study disease 
assessments; see supplementary appendix). Safety was assessed in patients receiving ≥1 
dose of mocetinostat. Pharmacokinetics were evaluated in all patients with sufficient data. 
Time-to-event efficacy endpoints were estimated using Kaplan-Meier methodology (see 
supplementary appendix). 
Results 
Patient disposition and baseline disease characteristics 
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Of 175 patients consenting to genomic screening, testing was feasible for 155 (89%; sample 
quantity/quality was insufficient for 20 patients). Frequently altered genes included TP53, 
ARID1A, MLL2 (KMT2D), KDM6A, MLL3 (KMT2C), RB1, and CDKN2A/B (Figure 1).  
Thirty-three (21%) patients had ≥1 of the 40 qualifying tumor mutations in CREBBP or EP300 
identified: 27 CREBBP mutations among 23 patients (15%); 13 EP300 mutations among 12 
patients (8%); mutations in both genes in 2 patients (1%). Each qualifying mutation was 
observed only once within the study. Qualifying CREBBP alterations were most commonly 
nonsense (8 [5%]), frameshift (7 [5%]) or missense (5 [3%]) mutations. EP300 mutations 
were most commonly missense mutations (5 [3%]). Non-qualifying mutations in CREBBP and 
EP300 (putative passenger mutations) were detected in 18 (12%) individuals (see 
Supplementary Table S3).  
Seventeen of 33 patients with qualifying mutations were enrolled into Stage 1 (Figure 2); 
baseline demographic and disease characteristics of the enrolled patients are shown in 
Table 1. Twenty-two qualifying mutations were identified in these 17 patients: 14 CREBBP 
mutations in 12 patients and 8 EP300 mutations in 7 patients; two patients had qualifying 
mutations of both CREBBP and EP300 (Supplementary Table S3). Sixteen patients with 
qualifying mutations were not enrolled, most commonly because they were receiving an 
earlier line of therapy (Figure 2). The patients received a median (range) of 2 (1–5) prior 
systemic therapies (Table 1) and all had discontinued mocetinostat at the time of analysis, 
most due to disease progression (53%) or AEs (24%; Figure 2). Based on Sponsor decision, 
the study was closed after enrolment of 17 patients, including 9 patients in the efficacy 
evaluable population (8 patients stopped mocetinostat treatment prior to on-study disease 
assessment: 4 due to AEs, 3 due to symptomatic deterioration and 1 withdrew consent); 
Stages 2 and 3 were not recruited. 
 
Efficacy 
One objective response was observed (efficacy evaluable population). This PR lasted 3.9 
months and occurred in a 67-year old man with disease restricted to lymph nodes. His 
primary tumor contained two qualifying EP300 missense mutations (G1347E and P925T) and 
other mutations (truncating mutations in ARID1A, MLL2 [KMT2D], and CHEK2; missense 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
mutation in ATM; and amplification of TERC and PRKCI). The ORR (95% CI) of 11% (0.3, 48%) 
was not statistically significant (null hypothesis of ≤15% could not be rejected, P=1.00). 
Stable disease lasting 3.5 months and 3.8 months was reported in two patients (22%) and 
progressive disease was reported in 6 patients (67%; Supplementary Figure S2). Median PFS 
(95% CI) was 57 days (23, 117 days) in the efficacy evaluable population. Estimated PFS at 4 
months was 10% (0, 40%); PFS at 1 year could not be estimated. Median OS (95% CI) was 3.5 
months (2.1, 15.7 months) and 1-year survival was 30% (10, 60%) in the ITT population (all 
patients receiving study medication). Similar efficacy results were observed in the efficacy 
evaluable and ITT populations.  
 
Safety 
Median (range) duration of mocetinostat therapy was 46 days (8, 225 days), and the 
cumulative median dose (range) administered was 930 mg (280, 7,730 mg). Median (range) 
relative dose intensity was 99% (37, 117%) during cycle 1 and 84% (14, 117%) in subsequent 
cycles. Eleven of the 17 enrolled patients initiated ≥2 treatment cycles. Mocetinostat dose 
was escalated from 70 mg TIW to 90 mg TIW in 9 patients (4 received ≤1 full cycle of 
mocetinostat 90 mg TIW). Five patients (29%) underwent dose reductions due to AEs (n=3, 
18%) or other reasons (n=2, 12%), and 14 patients (82%) had at least 1 dose interruption, 
most commonly due to AEs (n=11, 65%). 
All patients experienced ≥1 treatment-emergent (all causality) AE, and most (n=14, 82%) 
experienced ≥1 treatment-related AE. The most frequent treatment-emergent AEs were 
nausea (n=13, 77%), fatigue (n=12, 71%), decreased appetite (n=8, 47%) and diarrhea (n=8, 
47%; Table 2); these events were also the most frequent treatment-related AEs. Grade ≥3 
treatment-related AEs were fatigue and hyponatremia (n=2, 12%, each). Twenty-one 
treatment-emergent serious adverse events (SAEs) were reported in 10 patients (59%), 
including vomiting, lower gastrointestinal hemorrhage, abdominal pain and pericardial 
effusion (n=2, 12%, each). One SAE of pericardial effusion was assessed as related to 
mocetinostat (both pericardial effusion events resolved). Ten patients died during the study, 
all due to their underlying disease.  
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Pharmacokinetics 
Due to the limited blood sampling schedule for Stage 1, the 1 h post-dose sample was 
considered representative of maximum serum concentration (Cmax) based on data from 
prior studies (see supplementary appendix), and pharmacokinetic analyses were restricted 
to Cmax and time to Cmax (tmax
Following a single 70 mg dose of mocetinostat, mean C
).  
max was 105 ng/mL. Mean dose-
normalized Cmax was 1.2 ng/mL/mg and inter-subject variability (coefficient of variation, 
geometric mean) was 90%. Following multiple TIW doses of mocetinostat 50 mg and 90 mg, 
mean Cmax was 41 ng/mL and 39 ng/mL, respectively (Supplementary Table S4). The mean 
dose-normalized Cmax
 
 was 0.2 ng/mL/mg and inter-subject variability was 423%. 
Discussion 
Inactivating alterations of CREBBP and EP300 are relatively frequent (~13% and ~15%, 
respectively) in urothelial carcinoma 
14-16
 and are implicated in dysregulation of key 
acetylation pathways and oncogenesis 
17, 18
. Based on promising findings in urothelial 
carcinoma cell lines and tumor models (Supplementary Tables S1, S2 and Supplementary 
Figure S1), we postulated that patients with urothelial carcinoma and inactivating 
alterations in CREBBP and/or EP300 could be treated by Class I HDAC inhibition via a 
mechanism of increased histone acetylation leading to an open chromatin state with 
decreased transcriptional repression of tumor suppressor genes. While the maximum 
tolerated dose of mocetinostat as a single agent was determined to be 110 mg TIW in other 
tumor settings, a lower recommended dose of 90 TIW was considered for this study based 
on prior observations of pericardial infusion and balancing pharmacodynamic and clinical 
data as well as regulatory guidance 
19
. However, single-agent mocetinostat at doses up to 90 
mg TIW showed only modest activity in this cohort of heavily pretreated patients with 
factors indicative of poor prognosis. The ORR of 11% and of 9 evaluable patients only 1 
patient (with lymph node-only disease and multiple genomic alterations) remaining alive 
and progression-free for 4 months was not consistent with meaningful clinical activity. 
While mocetinostat-related AEs, including gastrointestinal events and fatigue, were 
consistent with the safety profiles reported in other settings 
11, 12, 20
, frequent dose 
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interruptions and reductions were required. Mocetinostat exposure (mean dose-normalized 
Cmax
Studies of other HDAC inhibitors in urothelial carcinoma patients reported mixed results, 
with responses seen with single-agent vorinostat but not when vorinostat was combined 
with doxorubicin or docetaxel 
 0.2 ng/mL/mg) was lower than in prior mocetinostat TIW trials (0.8 to 1.6 ng/mL/mg). 
It is feasible that underlying disease and prior treatments may have contributed to limited 
functional reserve, resulting in poor tolerability. These findings underscore the limitations of 
preclinical models in predicting clinical activity and toxicity issues related to anticancer 
treatments. Further evaluation of mocetinostat at lower doses may be useful to guide dose 
reduction guidance in future study protocols in order to maximize each patient’s exposure 
to treatment. 
21-23
. An ORR of 20% was reported in a small study of 
belinostat or panobinostat, and prolonged stable disease in one of 3 patients with urothelial 
carcinoma treated with entinostat plus 13-cis retinoic acid 
24, 25
. These data suggest that 
HDAC inhibitors can be active in urothelial carcinoma, but predictive biomarkers are needed 
for patient selection. To our knowledge, data regarding genomic predictors of response to 
HDAC inhibitors are limited. In a Phase II study of panobinostat in patients with relapsed 
diffuse large B-cell lymphoma, mutations in MEF2B were associated with response, while 14 
genes including TOX4, PSMD13 and CCNK were associated with resistance to vorinostat 
based on a study of human colon cancer cell lines 
26, 27
There was considerable genomic variation in CREBBP and EP300, with each qualifying 
mutation observed only once in this study. Interestingly, the patient with a confirmed PR 
harbored two EP300 mutations in trans, P925T and G1347E, suggesting biallelic loss of 
function in this pathway could be therapeutically meaningful; however this patient had 
lymph node-only metastasis, a favorable prognostic factor. It is feasible that mocetinostat 
activity might be greater as an earlier line of therapy when a longer treatment duration may 
be feasible and potentially confer meaningful disease-modifying activity. Furthermore, we 
hypothesized a mechanism of action of mocetinostat to reactivate transcription of tumor 
suppressor genes, but a relatively high frequency of inactivating alterations in the tumor 
. To our knowledge, this is the first 
clinical trial using genomic-based selection to identify patients with urothelial carcinoma for 
treatment with selective HDAC inhibition. This study demonstrates the feasibility of this 
approach while also providing genomic tumor characterization for this population.  
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suppressor genes TP53, CDKN2A/B, and RB1 may have limited the potential of epigenetic 
modulation by mocetinostat to induce tumor response. Potential future treatment 
strategies could include combining mocetinostat with an inhibitor of the PD1/ programmed 
death 1 ligand (PD-L1) to take advantage of the former’s potential immunomodulatory 
effects. Indeed, mocetinostat has been shown to increase expression of PD-L1 and augment 
PD-1/PD-L1 checkpoint blockade immunotherapy 
28
In summary, single-agent mocetinostat was associated with significant toxicities and limited 
activity in heavily pretreated patients with advanced/metastatic urothelial carcinoma and 
poor prognostic factors. Few patients received the intended dose of 90 mg TIW which may 
have compromised efficacy. Nevertheless, the clinical activity observed does not warrant 
further investigation as single agent in this setting. Mocetinostat is currently being 
investigated in other tumors and in combination with immunotherapy.  
. Other combination partners could be 
considered in the appropriate molecular context. 
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Tables and figures 
 
Table 1. Patient demographics and disease characteristics (ITT population) 
Patient characteristic Mocetinostat 
(N=17) 
Age, years; median (range) 67 (35–83) 
Male gender, n (%) 15 (88)  
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Race, n (%)  
White 15 (88) 
Asian 1 (6) 
Black 1 (6) 
Smoking history, n (%)  
Past smoker 8 (47) 
Never smoker 7 (41) 
Current smoker 2 (12) 
AJCC/UICC TNM Stage  
a
 
IVA 1 (6) 
IVB 16 (94) 
ECOG PS, n (%)  
0 5 (29) 
1 10 (59) 
2 2 (12) 
Bellmunt scores, n (%)  
b
 
0 5 (29) 
1 7 (41) 
2 5 (29) 
Baseline albumin (g/dL), median (range) 4.1 (3.1, 4.7) 
Baseline hemoglobin (g/dL), median (range) 12.5 (9.0, 14.5) 
Time from diagnosis of urothelial carcinoma, months (range) 26.4 (4.3–95.5) 
Location of disease, n (%)  
c
 
Lung  13 (77) 
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Liver 6 (35) 
Lymph node 15 (88) 
d
 
Bladder 3 (18) 
Bone 4 (24) 
Other 8 (47) 
Prior systemic therapy, n (%) 17 (100) 
Number of prior regimens, median (range) 2 (1–5) 
Patients with prior neoadjuvant/adjuvant regimens, n (%) 10 (59) 
Patients with prior advanced disease regimens, n (%) 12 (71) 
Patients who completed prior systemic therapy ≤3 months 
before starting study treatment, n (%)  
7 (41) 
Prior radiotherapy, n (%) 6 (35) 
Prior surgery, n (%) 15 (88) 
b
 
Cystectomy 10 (59) 
Transurethral resection of bladder tumor 9 (53) 
Urethrectomy 4 (24) 
Other 4 (24) 
AJCC/UICC TNM, American Joint Committee on Cancer / Union for International Cancer 
Control (T) tumor, (N) lymph nodes (M) metastasis; ITT; intent-to-treat (all patients receiving 
study medication); ECOG PS, Eastern Cooperative Oncology Group Performance Status 
a
Disease subsite (bladder, ureter, or renal pelvis) and disease stage were not specifically 
collected in this study; disease stage using definitions for bladder cancer were assessed 
retrospectively 
b
Bellmunt Scores were assessed retrospectively 
29
 
c
Patients may have more than 1 disease location or surgery 
d
Baseline disease was confined only to lymph nodes in two patients 
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Table 2. Treatment-emergent (all causality) adverse events occurring in at least 3 patients 
(safety population) 
MedDRA preferred term 
n (%) 
All grade 
(N=17) 
Grade 3/4 
(N=17) 
Nausea 13 (77) 1 (6) 
Fatigue 12 (71) 3 (18) 
Decreased appetite 8 (47) N/R 
Diarrhea 8 (47) N/R 
Hyponatremia 6 (35) 3 (18) 
Vomiting 6 (35) 1 (6) 
Abdominal pain 5 (29) 2 (12) 
Anemia 5 (29) 2 (12) 
Back pain 5 (29) N/R 
Constipation 5 (29) N/R 
Hypoalbuminemia 5 (29) N/R 
Hematuria 4 (24) N/R 
Muscular weakness 4 (24) N/R 
Alkaline phosphatase increased 3 (18) N/R 
Chills 3 (18) N/R 
Cough 3 (18) N/R 
Creatinine increased 3 (18) N/R 
Dehydration 3 (18) 1 (6) 
Dizziness 3 (18) N/R 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
Dysgeusia 3 (18) N/R 
Hypocalcemia 3 (18) N/R 
Lymphocyte count decreased 3 (18) 1 (6) 
Pain 3 (18) 1 (6) 
Urinary tract infections 3 (18) N/R 
MedDRA, Medical Dictionary for Regulatory Activities; N/R, not reported 
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Figure 1. Oncoprint of genetic alterations of 150 of the 155 patients in whom genetic 
profiling of tumor was feasible. 
Alterations include truncating mutations, gene amplifications, homozygous deletions, 
annotated recurrent missense mutations, and missense variants of uncertain significance 
(variants of unknown significance are excluded from the main study analysis) present in 
≥10% of the population. The 150 patients included 144 patients tested centrally at 
Foundation Medicine and 6 patients tested at local institutions. An arrow (↓) denotes a 
patient enrolled in the clinical trial (reports from 5 patients tested locally were not available, 
including 4 patients pre-screened using FoundationOne® testing and including two enrolled 
patients). 
a
 
In cases of CCND1 amplification, this co-occurred with FGF3, FGF4, or FGF19 amplification 
in >80% of cases.  In addition, a significant correlation for the co-occurrence of RB1 and 
TP53 mutations and CREBBP and STAG2 mutations and the mutual exclusivity of CDKN2A 
homozygous deletion and TP53 mutation or MDM2 amplification and TP53 mutation was 
observed. 
Figure 2. Patient disposition. 
a
Safety population and ITT population include all patients who received at least one dose of 
study medication 
b
 
Efficacy evaluable population includes all ITT patients who met prespecified entry criteria 
and have at least baseline and one on-study disease assessments adequate for evaluation 
using RECIST v1.1  
ITT, intent to treat 
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CREBBP 19%
EP300 15%
TP53 52%
CDKN2A/B 34%
ARID1A 31%
MLL2 (KMT2D) 29%
MLL3 (KMT2D) 21%
KDM6A 26%
RB1 20%
FGFR3 19%
ERBB2 17%
MDM2 17%
PIK3CA 15%
CCNDA1a 13%
STAG2 10%
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Patients consenting to genomic
prescreening (N=175 ) 
Enrolled (n=17)
• Safety population (n=17)a
• ITT population (n=17)a
• Efficacy evaluable population (n=9)b
Discontinued (n=17)
• Objective disease progression (n=9)
• Adverse event (n=4)
• Symptomatic deterioration (n=3)
• Patient decision (n=1)
Not enrolled (n=158)
• No qualifying mutation detected (n=142)
• Receiving earlier line of therapy (n=6)
• Died prior to screening (n=3)
• Health deterioration prior to screening (n=3)
• Patient decision (n=1)
• Other (n=3)
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